Blar i forfatter "Larsen, Alf Inge"

Viser treff 1-3 av 3

    • BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study 

      Munkhaugen, John; Ruddox, Vidar; Halvorsen, Sigrun; Dammen, Toril; Fagerland, Morten; Hernæs, Kjersti Helene; Vethe, Nils Tore; Prescott, Eva; Jensen, Svend Eggert; Rødevand, Olaf; Jortveit, Jarle; Bendz, Bjørn; Schirmer, Henrik; Kõber, Lars; Botker, Hans Erik; Larsen, Alf Inge; Vikenes, Kjell; Steigen, Terje; Wiseth, Rune; Pedersen, Terje Rolf; Edvardsen, Thor; Otterstad, Jan Erik; Atar, Dan (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-10-25)
      <p><i>Background - </i>Current guidelines on the use of β-blockers in post–acute myocardial infarction (MI) patients without reduced left ventricular ejection fraction (LVEF) are based on studies before the implementation of modern reperfusion and secondary prevention therapies. It remains unknown whether β-blockers will reduce mortality and recurrent MI in contemporary revascularized post-MI patients ...

    • Exploration of plasma lipids in mild cognitive impairment due to Alzheimer's disease 

      Bergland, Anne Katrine; Proitsi, Petroula; Kirsebom, Bjørn-Eivind; Sønnesyn, Hogne; Hye, Abdul; Larsen, Alf Inge; Xu, Jin; Legido-Quigley, Cristina; Rajendran, Lawrence; Fladby, Tormod; Aarsland, Dag (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-09-29)
      <p><i>Background: </i>Lipids have important structural roles in cell membranes and changes to these membrane lipids may influence β- and γ-secretase activities and thus contribute to Alzheimer’s disease (AD) pathology. <p><i>Objective:</i> To explore baseline plasma lipid profiling in participants with mild cognitive impairment (MCI) with and without AD pathology. <p><i>Methods: </i>We identified ...

    • Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial 

      Mecinaj, Albulena; Gulati, Geeta; Heck, Siri Lagethon; Holte, Espen; Fagerland, Morten Wang; Larsen, Alf Inge; Blix, Egil Støre; Geisler, Jürgen; Wethal, Torgeir; Omland, Torbjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-09-27)
      Background - Recent advances in the treatment algorithms of early breast cancer have markedly improved overall survival. However, anthracycline- and trastuzumab-associated cardiotoxicity may lead to dose-reduction or halt in potentially life-saving adjuvant cancer therapy. Early initiated neurohormonal blockade may prevent or attenuate the cardiotoxicity-induced reduction in cardiac function, but ...